193 related articles for article (PubMed ID: 35354467)
1. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
[TBL] [Abstract][Full Text] [Related]
2. MLL3 regulates the
Zhu C; Soto-Feliciano YM; Morris JP; Huang CH; Koche RP; Ho YJ; Banito A; Chen CW; Shroff A; Tian S; Livshits G; Chen CC; Fennell M; Armstrong SA; Allis CD; Tschaharganeh DF; Lowe SW
Elife; 2023 Jun; 12():. PubMed ID: 37261974
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer.
Lian J; Xu C; Chen X; Huang S; Wu D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1627-1640. PubMed ID: 35322299
[TBL] [Abstract][Full Text] [Related]
4.
Cho SJ; Yoon C; Lee JH; Chang KK; Lin JX; Kim YH; Kook MC; Aksoy BA; Park DJ; Ashktorab H; Smoot DT; Schultz N; Yoon SS
Clin Cancer Res; 2018 Dec; 24(24):6556-6569. PubMed ID: 30108106
[TBL] [Abstract][Full Text] [Related]
5. STAT3 regulated ARF expression suppresses prostate cancer metastasis.
Pencik J; Schlederer M; Gruber W; Unger C; Walker SM; Chalaris A; Marié IJ; Hassler MR; Javaheri T; Aksoy O; Blayney JK; Prutsch N; Skucha A; Herac M; Krämer OH; Mazal P; Grebien F; Egger G; Poli V; Mikulits W; Eferl R; Esterbauer H; Kennedy R; Fend F; Scharpf M; Braun M; Perner S; Levy DE; Malcolm T; Turner SD; Haitel A; Susani M; Moazzami A; Rose-John S; Aberger F; Merkel O; Moriggl R; Culig Z; Dolznig H; Kenner L
Nat Commun; 2015 Jul; 6():7736. PubMed ID: 26198641
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
Lee DH; Yu EJ; Aldahl J; Yang J; He Y; Hooker E; Le V; Mi J; Olson A; Wu H; Geradts J; Xiao GQ; Gonzalgo ML; Cardiff RD; Sun Z
PLoS One; 2019; 14(1):e0211153. PubMed ID: 30677079
[TBL] [Abstract][Full Text] [Related]
7. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
Jarrard DF; Sarkar S; Shi Y; Yeager TR; Magrane G; Kinoshita H; Nassif N; Meisner L; Newton MA; Waldman FM; Reznikoff CA
Cancer Res; 1999 Jun; 59(12):2957-64. PubMed ID: 10383161
[TBL] [Abstract][Full Text] [Related]
8. Loss of JUNB/AP-1 promotes invasive prostate cancer.
Thomsen MK; Bakiri L; Hasenfuss SC; Wu H; Morente M; Wagner EF
Cell Death Differ; 2015 Apr; 22(4):574-82. PubMed ID: 25526087
[TBL] [Abstract][Full Text] [Related]
9. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
Chen Z; Carracedo A; Lin HK; Koutcher JA; Behrendt N; Egia A; Alimonti A; Carver BS; Gerald W; Teruya-Feldstein J; Loda M; Pandolfi PP
Sci Signal; 2009 Aug; 2(84):ra44. PubMed ID: 19690330
[TBL] [Abstract][Full Text] [Related]
10. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
11. H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Bosgana P; Nikou S; Dimitrakopoulos FI; Logotheti S; Tzelepi V; Kalophonos C; Bravou V; Kourea E; Sampsonas F; Zolota V
Curr Mol Pharmacol; 2021; 14(6):1028-1036. PubMed ID: 32867667
[TBL] [Abstract][Full Text] [Related]
12. Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer.
Simigdala N; Chalari A; Sklirou AD; Chavdoula E; Papafotiou G; Melissa P; Kafalidou A; Paschalidis N; Pateras IS; Athanasiadis E; Konstantopoulos D; Trougakos IP; Klinakis A
Cell Mol Life Sci; 2023 Mar; 80(4):100. PubMed ID: 36933062
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus p16 gene therapy for prostate cancer.
Allay JA; Steiner MS; Zhang Y; Reed CP; Cockroft J; Lu Y
World J Urol; 2000 Apr; 18(2):111-20. PubMed ID: 10854145
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract][Full Text] [Related]
15. KMT2C, a histone methyltransferase, is mutated in a family segregating non-syndromic primary failure of tooth eruption.
Assiry AA; Albalawi AM; Zafar MS; Khan SD; Ullah A; Almatrafi A; Ramzan K; Basit S
Sci Rep; 2019 Nov; 9(1):16469. PubMed ID: 31712638
[TBL] [Abstract][Full Text] [Related]
16. KMT2C and KMT2D aberrations in breast cancer.
Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
Trends Cancer; 2024 Mar; ():. PubMed ID: 38453563
[TBL] [Abstract][Full Text] [Related]
17. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
18. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
[TBL] [Abstract][Full Text] [Related]
19. Genetic mutations in smoking-associated prostate cancer.
Elshafei A; Al-Toubat M; Feibus AH; Koul K; Jazayeri SB; Lelani N; Henry V; Balaji KC
Prostate; 2023 Sep; 83(13):1229-1237. PubMed ID: 37455402
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.
Konishi N; Nakamura M; Kishi M; Nishimine M; Ishida E; Shimada K
Am J Pathol; 2002 Apr; 160(4):1207-14. PubMed ID: 11943705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
